Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We evaluated the incidence of non-melanoma skin cancer (NMSC) across the tofacitinib RA development programme. NSMC incidence with tofacitinib / J.R. Curtis et al.
Introduction
Certain types of malignancies (lung, skin, lymphoma) are more prevalent in patients with rheumatoid arthritis (RA) than in the general population (1) (2) (3) . However, the mechanisms underlying this observation are not fully understood. One of the most commonly occurring malignancies associated with immunomodulatory therapy in patients with RA is non-melanoma skin cancer (NMSC) (4) . In patients with RA, an elevated risk of NMSC is associated with the use of biologic diseasemodifying anti-rheumatic drugs (bDMARDs), including tumour necrosis factor inhibitors (TNFi) (5) (6) (7) (8) (9) . There is also some evidence that risk of NMSC is further increased when TNFi are administered with methotrexate (MTX) (10, 11) . Therefore, it is important that the risk of NMSC should be characterised for immunomodulatory agents used to treat RA. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA (12) . The clinical efficacy and safety of tofacitinib 5 and 10 mg twice daily (BID), with or without background conventional synthetic DMARDs (csDMARDs), have been demonstrated in patients with active moderate to severe RA. These include randomised Phase 2 (13) (14) (15) (16) (17) and studies of up to 24 months' duration, and open-label, long-term extension (LTE) studies with up to 96 months' observation (25) , representing 6092 patients and 15,103 patient-years (pt-yrs) of exposure. The aim of this analysis was to determine the incidence of NMSC in the tofacitinib RA clinical development programme using pooled data from 6092 patients enrolled in randomised Phase 1, 2, 3 and open-label LTE studies. The effect of tofacitinib dose, time on study drug (over discrete 6-month intervals) and patient factors on the incidence of NMSC were investigated.
Patients and methods

Patients
Patients were ≥18 years of age with active moderate to severe RA, enrolled globally from North America, Europe, Latin America, Asia (including the Pacific Islands) and Australia. Patients had an inadequate response to MTX (NCT00413660 (15) , NCT00976599 (26) , NCT00603512 (16) , ORAL Scan (20) , ORAL Standard (21)), cs-DMARDs or bDMARDs (NCT01484561 (27) , NCT00147498 (14) , NCT00550-446 (13), NCT00687193 (17) , ORAL Solo (19) , ORAL Sync (22) ) or TNFi (ORAL Step (18) ). One Phase 1 study (NCT01262118 (28) ) and two Phase 2 studies (NCT01059864 (29) and NCT01359150 (30)) had no eligibility criteria for prior DMARD exposure (i.e. any or no prior DMARDs were acceptable). The Phase 3, ORAL Start study (23) was conducted in MTX-naïve patients. Exclusion criteria for all studies prohibited participation of patients with a malignancy or history of malignancy, with the exception of adequately treated or excised non-metastatic basal cell carcinoma (BCC), squamous cell carcinoma (SCC) of the skin or cervical carcinoma in situ. Patients with ≥1 prior resolved occurrence(s) of NMSC were eligible for inclusion, with no time restriction on the required date for the most recent NMSC prior to trial enrolment.
Study design
Reports of NMSC were analysed from patients pooled from one open-label and one randomised Phase 1 study (27, 31) , eight randomised, double-blind, Phase 2 studies (13-17, 29, 30, 32) , six randomised, double-blind, Phase 3 studies (ORAL Scan (20) (27, 28) . In Phase 2 studies (6 weeks' to 6 months' duration), tofacitinib was administered as 1, 3, 5, 10, 15 or 30 mg BID (20 mg once daily included in one study) either as monotherapy or with background MTX (13-17, 29, 30, 32) . In Phase 3 studies, tofacitinib 5 or 10 mg BID was administered as monotherapy (ORAL NSMC incidence with tofacitinib / J.R. Curtis et al. Start (23) and ORAL Solo (19)) or with csDMARDs, mainly MTX. Patients enrolled into LTE studies had participated in prior qualifying Phase 1, 2 or 3 studies and initiated treatment with tofacitinib 5 or 10 mg BID (30 August 2013 cut-off date; data collection and analyses ongoing; unlocked database, i.e. some values may change for the final, locked study databases). LTE study treatment was initiated with tofacitinib 5 mg BID (patients from Phase 2 studies) or tofacitinib 10 mg BID (patients from Phase 3 studies), with the exception of patients from China and Japan, who initiated treatment with tofacitinib 5 mg BID as per protocol (34) . In LTE studies, the tofacitinib dose could be reduced for safety reasons from 10 to 5 mg BID, or temporarily discontinued, at the investigator's discretion, for up to 28 consecutive days for adverse events (AEs) or surgical procedures. In the event of an inadequate response, the dose could be increased from 5 to 10 mg BID at the investigator's discretion. All studies contained a placebo control arm, except ORAL Start (23) 
Statistical analyses
Incidence rates (IR) for the first NMSC event occurring after exposure to tofacitinib were calculated across all doses of tofacitinib using combined data for all tofacitinib-treated patients in Phase 1, 2, 3 and LTE studies, and expressed as the number of unique patients with events per 100 pt-yrs of exposure, with 95% confidence intervals (CIs). IRs were calculated from the number of unique patients with an event, divided by the total exposure through the first NMSC event (for patients with events), or to discontinuation or data cut-off date (all other patients). The 95% CIs were based on maximum likelihood estimation, and Exact Poisson adjusted for exposure when IR is zero. Patients with adequately treated or excised nonmetastatic BCC or SCC were permitted to remain in the studies. The rate of recurrent or second incident of NMSC was reported descriptively. To evaluate the occurrence of NMSC with continued tofacitinib exposure, IRs were determined for non-overlapping 6-month intervals. Additionally, IRs were calculated for the following datasets: combined Phase 1, 2, 3 and LTE studies (P123LTE); combined Phase 1, 2 and 3 studies (P123); Phase 3 studies only (P3); combined LTE studies (LTE); and LTE study NCT00413699 (LTE1024). LTE1024 was analysed separately from the combined LTE studies, as the combined studies had a higher proportion of Japanese patients who predominantly received tofacitinib 5 mg BID.
Analysis of IRs for NMSC across subgroups
IRs for NMSC were assessed in patients receiving tofacitinib 5 and 10 mg BID in P123 and P3. LTE and LTE1024 analyses were based on the average total daily dose (TDD) for each patient (i.e. sum of all doses received divided by number of days' treatment up to the 2013 cut-off date or discontinuation): patients with a TDD ≥15 mg were assigned to the 10 mg BID group, while patients with a TDD <15 mg were assigned to the 5 mg BID group. IRs for NMSC were analysed for various additional subgroups based on the P123LTE study population, including background therapy (patients who received tofacitinib monotherapy or tofacitinib with background csDMARDs), prior exposure to TNFi and glucocorticoid use at baseline. Additionally, incidence was evaluated according to patient age at baseline (≥65 or <65 years), ethnicity, geographic location and prior history of NMSC.
Results
Patients included in the analysis
Overall, 6092 patients received ≥1 dose of tofacitinib and were included in the pooled P123LTE population. The mean age of tofacitinib-treated patients at baseline was 52.2 years (range: 18-86) and 82.7% of patients were female (Table I) . Five patients (0.1%) had a history of NMSC prior to study enrolment. Caucasians and Asians represented approximately 60% and 25%, respectively, of the P123LTE population (all tofacitinib doses). The corresponding proportions in the P3 population were approximately 63% and 24%. In the two LTE studies combined, the proportion of Caucasian and Asian patients was similar with tofacitinib 5 mg BID (46.5% and 43.2%, respectively), whereas with tofacitinib 10 mg BID it was 70.4% and 16.5%, respectively.
Overall incidence of NMSC in patients receiving tofacitinib
The combined exposure to tofacitinib in P123LTE was 15,103 pt-yrs. There were 125 occurrences of NMSC events in 83 tofacitinib-treated patients, resulting in an IR for the first NMSC event of 0.55 (95% CI, 0.45-0.69) per 100 pt-yrs (Fig. 1a) . Demographics and baseline characteristics for tofacitinib-NSMC incidence with tofacitinib / J.R. Curtis et al.
treated patients with NMSC events are presented in Table I . The median tofacitinib exposure time after the first NMSC event was 441 days (range: 0-2030). There were 71 occurrences of BCC (56.8%) in 52 patients and 51 occurrences of SCC (40.8%) in 39 patients, resulting in a BCC:SCC event ratio of approximately 1.4:1.0. Eleven of the 83 tofacitinib-treated patients with NMSC (13.3%) had both BCC and SCC events. IRs (95% CI) for SCC and BCC were 0.35 (0.26-0.45) and 0.26 (0.19-0.35), respectively. Only three out of these 83 patients reported 'NMSC other': two patients each with a single event of atypical fibroxanthoma and one patient with a single event of Merkel cell carcinoma. IRs for NMSC in the P123LTE population appeared to be stable over time (Fig. 1b) . IRs for NMSC in patients who received placebo, MTX or ADA in the P123 population were comparable with corresponding IRs for tofacitinib (Fig.  1a) . However, the exposure to placebo, MTX or ADA was much lower than for tofacitinib.
Recurring or second NMSC events in patients receiving tofacitinib
Of the 83 patients with NMSC during the study, 19 (22.9%) had ≥1 further occurrence or a second NMSC event whilst receiving tofacitinib, i.e. an additional event occurring at a different time or location. Among these 19 patients who had >1 NMSC event during the tofacitinib exposure period, the majority (n=11) had only two NMSC events in total; six and one patient(s) had three and four NMSC events overall, respectively, and one patient -a Tofacitinib dose groups in LTE studies were defined according to average TDD. ¥ Two and three patients in the tofacitinib 5 and 10 mg BID groups, respectively, had no demographic data available at the time of the data cut-off.
• Hispanic ethnicity was not captured as a separate category in Phase 3 studies; any patients of Hispanic ethnicity will be included as 'Other/unspecified'. || Rest of the world includes: Australia, China, India, Japan, Korea, Malaysia, New Zealand, Philippines, Taiwan and Thailand. bDMARD: biologic diseasemodifying anti-rheumatic drug; BID: twice daily; LTE: long-term extension; NC: not collected, Hispanic patients included in 'Other/unspecified' group; P123: Phase 1, Phase 2 and Phase 3 studies; P3: Phase 3; q2w, once every 2 weeks; SD: standard deviation; TDD: total daily dose.
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66-year-old Caucasian female from
Australia -had a total of 17 NMSC events (further discussion of this patient is included under subgroup analyses). Two of the 19 patients with ≥1 additional events had a history of NMSC prior to initiating tofacitinib; patients with a prior history of NMSC are also discussed in more detail under further subgroup analyses.
Incidence of NMSC according to tofacitinib dose received
Total exposure (pt-yrs) was similar for tofacitinib 5 and 10 mg BID in P123 (Fig. 1a ), but higher in LTE studies for tofacitinib 10 mg BID versus 5 mg BID (Fig. 1a , Table II ). In the P3 population, NMSC IRs were similar between tofacitinib dose groups, while in the ongoing, open-label LTE studies, both for LTE1024 and LTE, NMSC IRs were numerically higher with tofacitinib 10 mg BID versus 5 mg BID, although CIs overlapped (Table II) . Of the 83 tofacitinib-treated patients with NMSC, 20 were resident in Australia. Of these, nine patients had BCC as a first event, nine had SCC as a first event and two had 'NMSC other'. ADA 40 mg was administered every 2 weeks either as monotherapy or with background MTX. Exposure shown is cumulative exposure. ADA: adalimumab; BCC: basal cell carcinoma; BID: twice daily; CI: confidence interval; IR: incidence rate; LTE: long-term extension; MTX: methotrexate; N: total number of patients exposed to study treatment; n: number of unique patients with events; NMSC: non-melanoma skin cancer; P123: Phase 1, Phase 2 and Phase 3 studies; PBO: placebo; pts: patients; pt-yrs: patient-years; RA: rheumatoid arthritis; SCC: squamous cell carcinoma; Tofa: tofacitinib.
Further subgroup analyses
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( Fig. 2a) . The IR for NMSC in patients with prior TNFi exposure was significantly higher than for those who were TNFi-naïve with no overlap of CIs (Fig.  2a) . Among patients with glucocorticoid use reported at baseline, the NMSC IR was similar to that for patients with no baseline glucocorticoid use (Fig. 2a) .
In the pooled P123LTE population, the IR (95% CI) for NMSC was higher among patients ≥65 years of age ( 2b) . RoW contains the Pacific Islands, Australia and Asia: 20 of 21 patients in RoW who had NMSC were Australian and one patient was from Japan. Of the Australian patients, six had BCC, seven had SCC, five had both BCC and SCC, and two patients had 'NMSC other' (both atypical fibroxanthoma) as their only NMSC event. The Japanese patient had Merkel cell carcinoma. When the incidence of NMSC was evaluated according to ethnicity, the highest IR was (Fig. 2b) .
Discussion
In the present analysis, we explored the incidence of NMSC in the global population of patients who received tofacitinib during the RA clinical development programme. Across the tofacitinib RA programme, the IR for NMSC was relatively low and remained stable over time. As of the data cut-off for these analyses (30 August 2013), there were 83 patients with NMSC in tofacitinib RA clinical trials, representing 1.4% of the pooled P123LTE population. The overall IR for NMSC across the tofacitinib RA programme over 15,103 pt-yrs of exposure was consistent with IRs for NMSC in P3 studies of tofacitinib. IRs were similar between tofacitinib 5 and 10 mg BID doses in P3 studies, where randomisation between doses was balanced. In the P123 study population, an inverse dose relationship was observed, with a numerically lower IR for tofacitinib 10 mg BID compared with 5 mg BID. A numerical, but not statistically significant, difference (with overlapping CIs) was observed between IRs for tofacitinib 5 and 10 mg BID in the combined LTE population (majority of patients in LTE were from LTE1024). However, the IRs for NMSC in patients receiving tofaci- (10) . In the present study, Data cut-off: 30 August 2013. BID: twice daily; CI: confidence interval; IR: incidence rate (unique patients with events/100 pt-yrs); LTE: long-term extension; n: total number of patients; NMSC: non-melanoma skin cancer; P123: Phase 1, Phase 2 and Phase 3 studies; P3: Phase 3; pt-yrs: patient-years; RA: rheumatoid arthritis.
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limited conclusions can be drawn from the apparent increase in NMSC IR that was associated with prior TNFi therapy, owing to large differences in cumulative exposure between these two groups (2322 pt-yrs for prior TNFi; 12,781 ptyrs for TNFi-naïve). However, the IR for NMSC may also have been influenced by the cumulative effect of different immunosuppressants over time, including prior TNFi, other bDMARDs and csDMARDS. Nevertheless, our data reflect findings from a US Veterans' Affairs national database, which demonstrated a higher risk of NMSC in patients receiving TNFi therapy versus csDMARDs, with NMSC risk factors of older age, male gender and a history of prior malignancies (8) . The rate of occurrence of a second, or more, NMSC event in our analysis (22.9%; 19/83 patients) was slightly higher than in published literature (43) , although limited conclusions can be drawn due to low patient numbers. In the general population, the risk of developing a subsequent skin cancer of a specific type depends on the type of prior NMSC and number of prior skin tumours of that type, with specific follow-up strategies required for patients with BCC and SCC (44) . The analysis presented herein revealed that the IR for NMSC was highest in the USA. This may be explained by the fact that Caucasian patients living in geographic locations with year-round high ambient ultraviolet exposure levels are placed at greatest risk of developing NMSC (45) . Periodic skin examination is recommended for patients with RA treated with tofacitinib who are at increased risk for skin cancer (46) . Our analysis included data from LTE studies, which may have introduced certain limitations owing to non-randomised assignment of patients to the tofacitinib 5 or 10 mg BID treatment group based on qualifying study enrolment, protocol guidance and investigator discretion. Hence, exposure (pt-yrs) to tofacitinib 10 mg BID was greater than for tofacitinib 5 mg BID in the LTE studies, and some baseline characteristics, such as race, were not distributed evenly between doses, making interpretation of any dose differences uncertain. Similarly, in Phase 2 and 3 studies, exposure to placebo was comparatively low (as per protocol), and for placebo, MTX and ADA, the study population was small compared with pooled tofacitinib; therefore, IR differences between tofacitinib and control arms should be made with caution. Additionally, in the LTE studies, the tofacitinib dose could be modified at the investigator's dis- Results from patients who enrolled in the Phase 1, 2 or 3 optional background therapy studies, which allowed both background DMARDs and tofacitinib monotherapy in the same study, are not shown. CI: confidence interval; csDMARD: conventional synthetic disease-modifying antirheumatic drug; EU: Europe; GC: glucocorticoid; IR: incidence rate; LA: Latin America; LTE: long-term extension; mono: monotherapy; MTX: methotrexate; N: total number of patients exposed to study treatment; n: number of unique patients with events; NMSC: non-melanoma skin cancer; P123: Phase 1, Phase 2 and Phase 3 studies; pt-yrs: patient-years; RA: rheumatoid arthritis; RoW: rest of the world; TNFi: tumour necrosis factor inhibitor; Tofa: tofacitinib.
cretion based on efficacy and safety outcomes. As such, TDD was used to assign dosing groups in the LTE studies. However, the actual tofacitinib dose received during the LTE study was stable in the majority of patients; approximately 80% of patients did not change dose in the LTE studies. In conclusion, the IR for NMSC in the global population of patients with RA who received tofacitinib in P123 and LTE studies of the tofacitinib clinical development programme was consistent with published IRs for patients receiving TNFi and other bDMARDs in patients with RA, and remained stable over time. As in the general population, NMSC appeared to be more common in patients who were Caucasian, male, ≥65 years of age, had previous NMSC or previous exposure to TNFi. As there is a numerical, but not statistically significant, difference of NMSC in LTE with tofacitinib 10 mg BID compared with tofacitinib 5 mg BID, continued longer-term surveillance is necessary to further evaluate any potential risk of developing NMSC during tofacitinib treatment.
